Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Ltd is a leading India-based pharamceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
What Dr. files
- Others100
- Updates54
- Investor Meet51
- Important41
- Board Meeting9
- PPTs6
Here's the concise, retail-friendly summary: **1. Business Performance:** Dr. Reddy's reported Q1 FY27 revenues of ₹8,071 Cr (up 6% YoY) and a net profit of ₹443 Cr (up 69% YoY). The core business achieved healthy double-digit growth, though a significant ₹240 Cr impact from semaglutide API issues affected overall margins....
Dr. Reddy's reported its Q4 and full-year results, showing a diversified business model. Q4 revenues reached ₹7,516 Cr, up 12% year-over-year, with profit after tax (PAT) soaring 86% to ₹220 Cr. For the full year, revenues grew 3% to ₹33,593 Cr, and PAT jumped 24% to ₹4,285 Cr. Growth was...
Dr. Reddy's Q3 FY26 update shows revenue at ₹8,727 Cr, up 4.4% YoY, with EBITDA rising 11% YoY to ₹2,049 Cr. Profit attributable to shareholders was ₹1,210 Cr, down 14% YoY. The company reported a healthy net cash surplus of ₹3,069 Cr. Business performance saw double-digit growth in its base...
Dr. Reddy's delivered a strong Q2FY26. Revenue grew 9.8% YoY to ₹8,805 Cr, with Profit After Tax up 14% YoY to ₹1,437 Cr, translating to EPS of ₹17.25 (+15% YoY). EBITDA margin stood at 26.7%. Growth was broad-based, with India and Emerging Markets seeing robust double-digit growth. Europe surged due...
Here's a summary tailored to your preferences: **1. Financial Highlights:** Revenues hit ₹8,545 Cr (+11% YoY). EBITDA was ₹2,278 Cr (26.7% margin), PAT ₹1,418 Cr (17% margin). A ~22% annualised RoCE and ₹2,922 Cr net cash surplus highlight strong financial health. **2. Strategic Initiatives & Growth Drivers:** Focus on strengthening...